In today’s ACT Brief, we highlight new insights on recruitment bottlenecks from Citeline’s Matt Holms, UCB’s first-in-class ...
Learn how incorporating real-world data at study design can improve feasibility, reduce amendments, and align eligibility ...
New post hoc and pooled analyses from the OASIS 4 trial presented at ObesityWeek 2025 show that oral semaglutide 25 mg improves glycemic control, cardiovascular risk factors, and weight outcomes ...
Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...
Gain insight into how principal investigator scarcity, frequent protocol amendments, and uneven site performance undermine ...
In today’s ACT Brief, we highlight new insights from TransCelerate on streamlining clinical data to reduce burden, explore ...
In contrast, by utilizing technology-driven tools more effectively, we can drive efficiencies, improve communication, and ...
Kygevi (doxecitine and doxribtimine) earned FDA approval as the first treatment for thymidine kinase 2 deficiency, supported by data from a Phase II trial and multiple retrospective studies showing ...
Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and ...
Takeda has announced the completion of its 7-year, Phase III TIDES clinical trial (NCT02747927) evaluating the dengue vaccine, Qdenga. Along with an exploratory analysis of a booster dose, TIDES data ...
Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...
Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback